16615-80-8

Upstream product

• 79-37-8 oxalyl dichloride 
• 536-90-3 m-Anisidine 
• 79-07-2 Chloroacetamide 
• 4461-30-7 2-chloroacetylisocyanate 

Downstream Products

• 100805-90-1 1-{2-[1-(4-Chloro-phenyl)-1H-tetrazol-5-ylsulfanyl]-acetyl}-3-(3-methoxy-phenyl)-urea 
• 76979-65-2 1-(3-Methoxy-phenyl)-3-{2-[(4-oxo-4H-quinazolin-3-ylmethyl)-amino]-acetyl}-urea 
• 97399-36-5 1-{2-[5-(3,5-Dibromo-2-hydroxy-phenyl)-4-p-tolyl-4H-[1,2,4]triazol-3-ylsulfanyl]-acetyl}-3-(3-methoxy-phenyl)-urea 
• 100805-83-2 1-(3-Methoxy-phenyl)-3-[2-(1-phenyl-1H-tetrazol-5-ylsulfanyl)-acetyl]-urea 
• 76979-66-3 1-{2-[(6-Bromo-4-oxo-4H-quinazolin-3-ylmethyl)-amino]-acetyl}-3-(3-methoxy-phenyl)-urea 
• 76979-67-4 1-(3-Methoxy-phenyl)-3-{2-[(6-nitro-4-oxo-4H-quinazolin-3-ylmethyl)-amino]-acetyl}-urea 
• 80416-42-8 1-(3-Methoxy-phenyl)-3-[2-(4-oxo-3-phenyl-3,4-dihydro-quinazolin-2-ylsulfanyl)-acetyl]-urea 
• 80416-48-4 1-[2-(6-Bromo-4-oxo-3-phenyl-3,4-dihydro-quinazolin-2-ylsulfanyl)-acetyl]-3-(3-methoxy-phenyl)-urea 
• 89174-67-4 1-[2-(5,6-Diphenyl-[1,2,4]triazin-3-ylsulfanyl)-acetyl]-3-(3-methoxy-phenyl)-urea 

Relevant academic research and scientific papers

Design, Synthesis, and Antitumor Activity Evaluation of Trifluoromethyl-Substituted Pyrimidine Derivatives Containing Urea Moiety

Abstract: In order to find efficient new antitumor drugs, a series of novel pyrimidine derivatives containing urea moiety were designed and synthesized, and the antitumor activity of four human tumor cells was evaluated by MTT analysis. The results showed that most of the target compounds exhibited moderate antitumor activity. In particular, the IC50 (concentration required to achieve 50% inhibition of the tumor cell proliferation) value of compound 2-((4-(4-ethylphenoxy)-6-(trifluoromethyl)pyrimidin-2-yl)thio)-N-((4-ethylphenyl)carba-moyl)acetamide for MGC-803 (human gastric carcinoma cell line) was 2.51 ± 0.17 μmol L–1, the anti-proliferative activity was significantly better than the positive control drug 5-fluorouracil. Molecular docking revealed that this compound can bind well to the active site of epidermal growth factor receptor (EGFR), and it may become a potential antitumor drug.

Quinoxaline-based inhibitors of Ebola and Marburg VP40 egress

We prepared a series of quinoxalin-2-mercapto-acetyl-urea analogs and evaluated them for their ability to inhibit viral egress in our Marburg and Ebola VP40 VLP budding assays in HEK293T cells. We also evaluated selected compounds in our bimolecular complementation assay (BiMC) to detect and visualize a Marburg mVP40–Nedd4 interaction in live mammalian cells. Antiviral activity was assessed for selected compounds using a live recombinant vesicular stomatitis virus (VSV) (M40 virus) that expresses the EBOV VP40 PPxY L-domain. Finally selected compounds were evaluated in several ADME assays to have an early assessment of their drug properties. Our compounds had low nM potency in these assays (e.g., compounds 21, 24, 26, 39), and had good human liver microsome stability, as well as little or no inhibition of P450 3A4.